Elizabeth B. Andrews

Expertise

Drug Safety
Therapeutic Risk Management
Therapeutic Outcomes and Safety

Biography

Elizabeth Andrews, PhD and MPH, is currently the vice president of Pharmacoepidemiology and Risk Management at RTI Health Solutions, a business unit of RTI International, which she joined in 2001. Dr. Andrews provides consultation to pharmaceutical companies and the U.S. Food and Drug Administration on epidemiology and therapeutic risk management and directs research programs that evaluate drug safety and compliance with prescribing and treatment guidelines. While her experience has spanned most therapeutic areas, she has worked extensively in the areas of HIV, sexually transmitted diseases, birth defects and neonatal health, and irritable bowel syndrome. Dr. Andrews has 18 years of experience working within the pharmaceutical industry, where she most recently served as the vice president of Worldwide Epidemiology at GlaxoSmithKline. She is a fellow and past president of the International Society for Pharmacoepidemiology and a member of the editorial board of the Journal of Pharmacoepidemiology and Drug Safety.

Education

PhD, Epidemiology, University of North Carolina at Chapel Hill; MPH, Health Policy and Administration, University of North Carolina at Chapel Hill.

Selected Publications

Rubino, A., Roskell, N.S., Tennis, P., Mines, D., Weich, S., & Andrews, E. (2007 Feb 03). Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: Retrospective cohort study. BMJ, 334 (7587):242-245.

Mann, R., & Andrews, E.B. (Ed.). (2007). Pharmacovigilance, 2nd Edition. Chichester, West Sussex, England: John Wiley & Sons, Ltd.

Chambers, C.D., & Andrews, E.B. (2007). Drug safety in pregnancy. In R.D. Mann, & E.B. Andrews (Ed.), Pharmacovigilance, 2nd ed. Chichester, West Sussex, England: John Wiley & Sons, Inc.

Boswell, D.A., & Andrews, E.B. (2007). Ethical oversight, consent and confidentiality. In Mann, R.D., & E.B. Andrews (Ed.), Pharmacovigilance, 2nd ed. Chichester, West Sussex, England: John Wiley & Sons, Inc.

Hirst, C., Cook, S., Dai, W., Perez-Gutthann, S., & Andrews, E. (Dec 2006). A call for international harmonization in therapeutic risk management. Pharmacoepidemiology and Drug Safety, 15 (12):839-849.

Miller, D.P., Bennett, L., Hollis, K.A., Tennis, P., Cook, S.F., & Andrews, E. (September 2006). A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. Alimentary Pharmacology and Therapeutics, 24 (5):869-878.

Williams, R.E., Black, C.L., Kim, H.Y., Andrews, E.B., Mangel, A.W., Buda, J.J., & Cook, S.F. (Jun 2006). Determinants of healthcare-seeking behaviour among subjects with irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 23 (11):1667-1675.

Haynes, K., Karlawish, J., & Andrews, E.B. (2006). Bioethical issues in pharmacoepidemiologic research. In Strom, B.L., & S.E. Kimmel (Ed.), Textbook of Pharmacoepidemiology (pp. 301-310). Chichester, West Sussex, England: John Wiley & Sons, Inc.

Andrews, E.B., Eaton, S.C., Hollis, K.A., Hopkins, J.S., Ameen, V.Z., Hamm, L.R., Mangel, A.W., Tennis, P., & Cook, S.F. (2005). Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Alimentary Pharmacology and Therapeutics, 2005 (22):935-942.

Casarett, D., Karlawish, J., Andrews, E., & Caplan, A. (2005). Bioethical issues in pharmacoepidemiology research. In B.L. Strom (Ed.), Pharmacoepidemiology. 4th ed. (pp. 587-598). Chichester, West Sussex, England: John Wiley & Sons, Inc.

View all publications by Elizabeth B. Andrews…